BTK and B-cell chronic lymphocytic leukemia: It suppresses and blocks BTK enzyme activity by covalently binding to the same ATP domain [4,5], which significantly improves long-term outcomes for untreated or relapsed/refractory CLL patients in phase 3 trials when compared to chemo(immuno)therapy alone or in combination [6,7].